The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Systemic Therapy for Colorectal Cancer
Abstract
Colorectal cancer is one of the most commonly diagnosed malignant diseases, with an estimated 1,023,000 new cases and 529,000 deaths worldwide each year. This review considers recently developed cytotoxic chemotherapies and biologic agents that are effective against colorectal cancer and assesses their use as treatments for metastatic disease and as components of adjuvant therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
American Joint Committee on Cancer (2002) · Springer eBooks · doi:10.1007/978-1-4757-3656-4 · Cited by 6,379
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Self-citationGlobocan 2000 : cancer incidence, mortality and prevalence worldwide
Ferlay, J., Pisani, P., & Parkin, D. M. (2001) · Medical Entomology and Zoology · Cited by 1,579
The classification of cancer of the rectum
Dukes, C. E. (1932) · The Journal of Pathology and Bacteriology · doi:10.1002/path.1700350303 · Cited by 1,505
Benson, A. B., Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., Krzyzanowska, M. K., Maroun, J., McAllister, P., Van Cutsem, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.063 · Cited by 1,430
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Grothey, A., Sargent, D., Goldberg, R. M., & Schmoll, H.-J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.037 · Cited by 1,070
Van Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.21.4097 · Cited by 1,032
Gill, S., Loprinzi, C. L., Sargent, D. J., Thomé, S. D., Alberts, S. R., Haller, D. G., Benedetti, J., Francini, G., Shepherd, L. E., Francois Seitz, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.059 · Cited by 1,021
Rougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03085-2 · Cited by 992
A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients
Sargent, D. J., Goldberg, R. M., Jacobson, S. D., Macdonald, J. S., Labianca, R., Haller, D. G., Shepherd, L. E., Seitz, J. F., & Francini, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010957 · Cited by 986
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.301 · Cited by 981
Innocenti, F., Undevia, S. D., Iyer, L., Xian Chen, P., Das, S., Kocherginsky, M., Karrison, T., Janisch, L., Ramírez, J., Rudin, C. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.173 · Cited by 964
Kemeny, N., Huang, Y., Cohen, A. M., Shi, W., Conti, J. A., Brennan, M. F., Bertino, J. R., Turnbull, A. D. M., Sullivan, D., Stockman, J., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912303412702 · Cited by 957
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-5-199503010-00001 · Cited by 925
de Gramont, A., Bosset, J. F., Milan, C., Rougier, P., Bouché, O., Etienne, P. L., Morvan, F., Louvet, C., Guillot, T., François, E., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.808 · Cited by 908
Lokich, J. J., Ahlgren, J. D., Gullo, J. J., Philips, J. A., & Fryer, J. G. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.425 · Cited by 773
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
Iyer, L., Das, S., Janisch, L., Wen, M., Ramírez, J., Karrison, T., Fleming, G. F., Vokes, E. E., Schilsky, R. L., & Ratain, M. J. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500072 · Cited by 720
Scheithauer, W., Rosen, H., Kornek, G. V., Sebesta, C., & Depisch, D. (1993) · BMJ · doi:10.1136/bmj.306.6880.752 · Cited by 654
Rothenberg, M. L., Oza, A. M., Bigelow, R. H., Berlin, J. D., Marshall, J. L., Ramanathan, R. K., Hart, L. L., Gupta, S., Garay, C. A., Burger, B. G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.126 · Cited by 646
Rixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K., & Fojo, T. (1996) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)81490-6 · Cited by 615
Sakata, Y., Ohtsu, A., Horikoshi, N., Sugimachi, K., Mitachi, Y., & Taguchi, T. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00211-1 · Cited by 565
Allen-Mersh, T. G., Earlam, S., Fordy, C., Abrams, K., & Houghton, J. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90750-1 · Cited by 534
Mamounas, E., Wieand, S., Wolmark, N., Bear, H. D., Atkins, J. N., Song, K., Jones, J., & Rockette, H. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1349 · Cited by 531
Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy
Baselga, J. (2002) · The Oncologist · doi:10.1634/theoncologist.7-2004-2 · Cited by 510
Wolmark, N., Rockette, H., Mamounas, E., Jones, J., Wieand, S., Wickerham, D. L., Bear, H. D., Atkins, J. N., Dimitrov, N. V., Glass, A. G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3553 · Cited by 493
Efficacy of Adjuvant Fluorouracil and Folinic Acid in B2 Colon Cancer
(1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1356 · Cited by 444
Meta-Analysis Group In Cancer (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.5.252 · Cited by 441
Machover, D., Diaz-Rubio, E., de Gramont, A., Schilf, A., Gastiaburu, J.-J., Brienza, S., Itzhaki, M., Metzger, G., N'Daw, D., Vignoud, J., et al. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010489 · Cited by 434
Rothenberg, M. L., Meropol, N. J., Poplin, E. A., Van Cutsem, E., & Wadler, S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3801 · Cited by 425
Kemeny, M. M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1499 · Cited by 421
Mayer, A., Takimoto, M., Fritz, E., Schellander, G., Kofler, K., & Ludwig, H. (1993) · Cancer · doi:10.1002/1097-0142(19930415)71:8<2454::aid-cncr2820710805>3.0.co;2-2 · Cited by 412
(2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.104 · Cited by 389
Chemotherapy for Colorectal Cancer
Wood, A. J. J., & Moertel, C. G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199404213301608 · Cited by 372
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., & Glick, J. H. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.12.2936 · Cited by 369
Lorenz, M., Müller, H.-H., Schramm, H., Gassel, H.-J., Rau, H.-G., Ridwelski, K., Hauss, J., Stieger, R., Jauch, K.-W., Bechstein, W. O., et al. (1998) · Annals of Surgery · doi:10.1097/00000658-199812000-00006 · Cited by 356
Douillard, J.-Y., Hoff, P. M., Skillings, J. R., Eisenberg, P., Davidson, N., Harper, P., Vincent, M. D., Lembersky, B. C., Thompson, S., Maniero, A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.123 · Cited by 323
Oxaliplatin-safety profile: neurotoxicity
GROTHEY, A. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00399-3 · Cited by 319
Bécouarn, Y., Ychou, M., Ducreux, M., Borel, C., Bertheault-Cvitkovic, F., Seitz, J. F., Nasca, S., Nguyen, T. D., Paillot, B., Raoul, J. L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2739 · Cited by 301
Carmichael, J., Popiela, T., Radstone, D., Falk, S., Borner, M., Oza, A., Skovsgaard, T., Munier, S., & Martin, C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.129 · Cited by 268
Raymond, E., Buquet-Fagot, C., Djelloul, S., Mester, J., Cvitkovic, E., Allain, P., Louvet, C., & Gespach, C. (1997) · Anti-Cancer Drugs · doi:10.1097/00001813-199710000-00009 · Cited by 235
Díaz-Rubio, E., Sastre, J., Zaniboni, A., Labianca, R., Cortés-Funes, H., de Braud, F., Boni, C., Benavides, M., Dallavalle, G., & Homerin, M. (1998) · Annals of Oncology · doi:10.1023/a:1008200825886 · Cited by 228
Levi, F., Perpoint, B., Garufi, C., Focan, C., Chollet, P., Depres-Brummer, P., Zidani, R., Brienza, S., Itzhaki, M., Iacobelli, S., et al. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90073-o · Cited by 218
UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan
Ando, Y., Saka, H., Asai, G., Sugiura, S., Shimokata, K., & Kamataki, T. (1998) · Annals of Oncology · doi:10.1023/a:1008438109725 · Cited by 207
Ward, S., Kaltenthaler, E., Cowan, J., & Brewer, N. (2003) · Health Technology Assessment · doi:10.3310/hta7320 · Cited by 162
Köhne, C.-H., Wils, J., Lorenz, M., Schöffski, P., Voigtmann, R., Bokemeyer, C., Lutz, M., Kleeberg, U., Ridwelski, K., Souchon, R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.122 · Cited by 160
Hemming, A. W., Davis, N. L., Kluftinger, A., Robinson, B., Quenville, N. F., Liseman, B., & Lcriche, J. (1992) · Journal of Surgical Oncology · doi:10.1002/jso.2930510304 · Cited by 128
Hahn, R. G., Moertel, C. G., Schutt, A. J., & Bruckner, H. W. (1975) · Cancer · Cited by 116
Complications of Hepatic Artery Infusion : A Review of 4580 Reported Cases
Barnett, K. T., & Malafa, M. P. (2001) · International Journal of Gastrointestinal Cancer · doi:10.1385/ijgc:30:3:147 · Cited by 94
Oral fluoropyrimidines in the treatment of colorectal cancer
Meropol, N. J. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00226-3 · Cited by 91
Klein, C. E. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.129502 · Cited by 85
Johnston, P. G., Benson, A. B., Catalano, P. J., Rao, M. S., O'Dwyer, P. J., & Allegra, C. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.039 · Cited by 82
Weh, H. J., Wilke, H., Dierlamm, J., Klaassen, U., Siegmund, R., Illiger, H. J., Schalhorn, A., Kreuser, E. D., Hilgenfeld, U., Steinke, B., et al. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058799 · Cited by 76
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B., Pitot, H., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.3621 · Cited by 70
Grothey, A. F., Büchele, T., Kroening, H., Ridwelski, K., Reichardt, P., Kretzschmar, A., Clemens, M. R., & Schmoll, H. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)81446-5 · Cited by 60
Wolmark, N., Wieand, S., Lembersky, B. C., Colangelo, L. H., Smith, R. L., & Pazdur, R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.3508 · Cited by 59
Epithelial growth factor receptor interacting agents
Baselga, J. M., & Albanell, J. (2002) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(02)00055-2 · Cited by 51
Innocenti, F., Iyer, L., & Ratain, M. J. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039050-00001 · Cited by 42
Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer
Smyth, J. F., Hardcastle, J. D., Denton, G., Alderson, D., Grace, R. H., Mansi, J., Yosef, H. M. A., Nordle, Ö., Lauri, H., & Wählby, S. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059365 · Cited by 36
Mayer, R. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.21.4093 · Cited by 32
Self-citationAdjuvant therapy of resectable rectal cancer
Minsky, B. D. (2002) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(02)00037-3 · Cited by 18
Adjuvant Therapy of Colorectal Cancer: Why We Still Don't Know
Buyse, M. (1988) · JAMA · doi:10.1001/jama.1988.03720240033031 · Cited by 18
Research works printed but not linked: 31
- 2000, Cochrane Database Syst Rev, 2, CD001545
- Sobrero A, 2000, Semin Oncol, 27, 72
- Zhang ZG, 1992, Semin Oncol, 19, 10
- 10.1002/(SICI)1097-0142(19960715)78:2<300::AID-CNCR17>3.0.CO;2-# · doi:10.1002/(sici)1097-0142(19960715)78:2<300::aid-cncr17>3.0.co;2-#
- 10.1002/(SICI)1097-0142(19960715)78:2<294::AID-CNCR16>3.0.CO;2-R · doi:10.1002/(sici)1097-0142(19960715)78:2<294::aid-cncr16>3.0.co;2-r
- 10.1002/1097-0142(197504)35:4<1031::AID-CNCR2820350403>3.0.CO;2-N · doi:10.1002/1097-0142(197504)35:4<1031::aid-cncr2820350403>3.0.co;2-n
- Pentheroudakis G, 2002, Anticancer Res, 22, 3589
- Sulkes A, 1998, J Clin Oncol, 16, 3461, 10.1200/JCO.1998.16.10.3461 · doi:10.1200/jco.1998.16.10.3461
- 10.1001/jama.259.24.3571 · doi:10.1001/jama.259.24.3571 · Paper page
- Haller DG, 1993, Adv Exp Med Biol, 339, 51, 10.1007/978-1-4615-2488-5_6 · doi:10.1007/978-1-4615-2488-5_6
- Haller DG, 1998, Proc Am Soc Clin Oncol, 17, 982
- 10.1002/(SICI)1097-0142(19980901)83:5<882::AID-CNCR12>3.0.CO;2-R · doi:10.1002/(sici)1097-0142(19980901)83:5<882::aid-cncr12>3.0.co;2-r
- 10.1007/s002800051077 · doi:10.1007/s002800051077
- Mathijssen RH, 2001, Clin Cancer Res, 7, 2182
- Goldberg RM, 2004, J Clin Oncol, 22, 3621, 10.1200/jco.2004.22.14_suppl.3621 · doi:10.1200/jco.2004.22.14_suppl.3621
- Hwang JJ, 2003, Oncology (Huntingt), 17, 37
- Raymond E, 1998, Semin Oncol, 25, 4
- Raymond E, 2002, Mol Cancer Ther, 1, 227
- Grothey A, 2003, Prog Proc Am Soc Clin Oncol, 22, 255
- 10.1634/theoncologist.7-suppl_4-2 · doi:10.1634/theoncologist.7-suppl_4-2 · Paper page
- Saltz L, 2001, Prog Proc Am Soc Clin Oncol, 20, 3a
- 10.1200/JCO.2004.10.182 · DOI · Paper page
- Kabbinavar F, 2004, J Clin Oncol, 22, 3516, 10.1200/jco.2004.22.14_suppl.3516 · doi:10.1200/jco.2004.22.14_suppl.3516
- Saltz L, 2003, Prog Proc Am Soc Clin Oncol, 22, 204a
- Berlin JD, 2002, Oncology (Huntingt), 16, 13
- 10.1007/s11912-001-0008-5 · doi:10.1007/s11912-001-0008-5
- Kornmann M, 2003, Clin Cancer Res, 9, 4116
- 10.1016/S1091-255X(02)00018-5 · doi:10.1016/s1091-255x(02)00018-5
- Berglund A, 2002, Anticancer Res, 22, 3653
- Aschele C, 2000, Clin Cancer Res, 6, 4797
- 10.1038/sj.bjc.6601487 · doi:10.1038/sj.bjc.6601487
Cited by
Molecular Basis of Colorectal Cancer
Markowitz, S. D., & Bertagnolli, M. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804588 · Cited by 2,052
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431
Self-citationDetection and quantification of mutations in the plasma of patients with colorectal tumors
Diehl, F., Li, M., Dressman, D., He, Y., Shen, D., Szabo, S., Diaz, L. A., Goodman, S. N., David, K. A., Juhl, H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507904102 · Cited by 1,188
Actual 10-Year Survival After Resection of Colorectal Liver Metastases Defines Cure
Tomlinson, J. S., Jarnagin, W. R., DeMatteo, R. P., Fong, Y., Kornprat, P., Gonen, M., Kemeny, N., Brennan, M. F., Blumgart, L. H., & D'Angelica, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0833 · Cited by 1,187
Metadata
- Authors
- Meyerhardt, J. A., & Mayer, R. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-02-03
- Volume
- 352
- Issue
- 5
- Pages
- 476-487
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2069305509
- Cited by
- 1,043
- References
- 77
- FWCI
- 30.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.